邓江,贾锋鹏

• 1:重庆医科大学附属第一医院心内科
• 2:重庆医科大学研究生院

摘要(Abstract)：

卵圆孔未闭（PFO）是一种广泛存在的先天性心血管结构异常，已被证实为隐源性卒中、偏头痛等多种疾病的危险因素。多项临床随机对照研究表明，经皮导管封堵器置入的获益高于单纯药物治疗。然而，目前这种永久性金属置入装置存在封堵器相关并发症发生风险、阻碍经房间隔路径进入左心房介入操作等不良影响。理想化的PFO封堵方法应该没有永久性异物存留，包括生物可降解PFO封堵器、射频消融和机械损伤闭合PFO、经皮导管缝合PFO等多种非永久置入性介入治疗方法。现就相关进展进行综述。

关键词(KeyWords)： 卵圆孔未闭;无置入;射频消融;缝合;生物可降解封堵器

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 邓江,贾锋鹏

参考文献(References)：

• [1] Cho KK,Khanna S,Lo P,et al. Persistent pathology of the patent foramen ovale:a review of the literature[J]. Med J Aust,2021,215(2):89-93.
• [2]张玉顺，蒋世良，朱鲜阳.卵圆孔未闭相关卒中预防中国专家指南[J].心脏杂志，2021,33(1):1-10.
• [3] Hagen PT,Scholz DG,Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life:an autopsy study of 965 normal hearts[J]. Mayo Clin Proc,1984,59(1):17-20.
• [4] Mckenzie JA,Edwards WD,Hagler DJ. Anatomy of the patent foramen ovale for the interventionalist[J]. Catheter Cardiovasc Interv,2009,73(6):821-826.
• [5] Windecker S,Stortecky S,Meier B. Paradoxical Embolism[J].J Am Coll Cardiol,2014,64(4):403-415.
• [6] Lee PH,Song JK,Kim JS,et al. Cryptogenic stroke and highrisk patent foramen ovale:the DEFENSE-PFO trial[J]. J Am Coll Cardiol,2018,71(20):2335-2342.
• [7] Saver JL,Carroll JD,Thaler DE,et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke[J].N Engl J Med,2017,377(11):1022-1032.
• [8] Mas J,Derumeaux G,Guillon B,et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J]. N Engl J Med,2017,377(11):1011-1021.
• [9] S?ndergaard L,Kasner SE,Rhodes JF,et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J].N Engl J Med,2017,377(11):1033-1042.
• [10] Dowson A,Mullen MJ,Peatfi eld R,et al. Migraine intervention with STARFlex technology(MIST)trial:a prospective,multicenter, double-blind, sham-controlled trial to evaluate the ef fectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache[J].Circulation,2008,117(11):1397-1404.
• [11] Mattle HP,Evers S,Hildick-Smith D,et al. Percutaneous closure of patent foramen ovale in migraine with aura,a randomized controlled trial[J]. Eur Heart J,2016,37(26):2029-2036.
• [12] Tobis JM,Charles A,Silberstein SD,et al. Percutaneous closure of patent foramen ovale in patients with migraine:the PREMIUM trial[J]. J Am Coll Cardiol,2017,70(22):2766-2774.
• [13] Zhang Y,Wang H,Liu L. Patent foramen ovale closure for treating migraine:a meta-analysis[J]. J Interv Cardiol,2022,2022:6456272.
• [14] Merkler AE,Gialdini G,Yaghi S,et al. Safety outcomes after percutaneous transcatheter closure of patent foramen ovale[J].Stroke,2017,48(11):3073-3077.
• [15] Staubach S,Steinberg DH,Zimmermann W,et al. New onset atrial fi brillation after patent foramen ovale closure[J]. Catheter Cardiovasc Interv,2009,74(6):889-895.
• [16] Johnson JN,Marquardt ML,Ackerman MJ,et al. Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure[J]. Catheter Cardiovasc Interv,2011,78(2):254-261.
• [17] Kibler M,Marzak H,Jesel L,et al. High-grade atrioventricular block occurring during percutaneous closure of patent foramen ovale:a case report[J]. Eur Heart J Case Rep,2020,4(4):1-5.
• [18] Abaci A,Unlu S,Alsancak Y,et al. Short and long term complications of device closure of atrial septal defect and patent foramen ovale:meta-analysis of 28,142 patients from 203studies[J]. Catheter Cardiovasc Interv,2013,82(7):1123-1138.
• [19] Sigusch HH,Zimmermann B,Kuntze T,et al. Cardiac tamponade following aortic root erosion by an amplatzer PFOoccluder in a 41-year-old woman:only a matter of sizing[J]?J Cardiol Cases,202,23(3):123-126.
• [20] Amin Z,Hijazi ZM,Bass JL,et al. PFO closure complications from the AGA registry[J]. Catheter Cardiovasc Interv,2008,72(1):74-79.
• [21] Resor CD,Goldminz AM,Shekar P,et al. Systemic allergic contact dermatitis due to a GORE CARDIOFORM septal occluder device:a case report and literature review[J]. JACC Case Rep,2020,2(12):1867-1871.
• [22] Tang B,Su F,Sun X,et al. Recent development of transcatheter closure of atrial septal defect and patent foramen ovale with occluders[J]. J Biomed Mater Res B Appl Biomater,2018,106(1):433-443.
• [23] Lin C,Liu L,Liu Y,et al. Recent developments in nextgeneration occlusion devices[J]. Acta Biomater,2021,128:100-119.
• [24] Jux C,Bertram H,Wohlsein P,et al. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix:development and preclinical evaluation of the BioSTAR device[J]. J Am Coll Cardiol,2006,48(1):161-169.
• [25] Mullen MJ,Hildick-Smith D,De Giovanni JV,et al. BioSTAR evaluation study(BEST):a prospective, multicenter,phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts[J]. Circulation,2006,114(18):1962-1967.
• [26] Karagianni A,Abrahamsson P,Furen?s E,et al. Closure of persistent foramen ovale with the BioSTAR biodegradable PFO closure device:feasibility and long-term outcome[J]. Scand Cardiovasc J,2011,45(5):267-272.
• [27] Vottero GV,Niclauss L,Marcucci C,et al. Late migration of percutaneous bio-absorbable devices-a word of caution[J].J Card Surg,2012,27(2):183-185.
• [28] Suligoj NC,Rojko M,Suligoj B,et al. Long-term transesophageal echocardiography after patent foramen ovale closure by BioSTAR and Amplatzer patent foramen ovale occluders[J]. Catheter Cardiovasc Interv,2020,95(3):349-354.
• [29] Happel CM,Laser KT,Sigler M,et al. Single center experience:implantation failures,early,and late complications after implantation of a partially biodegradable ASD/PFO-device(BioStar?)[J]. Catheter Cardiovasc Interv,2015,85(6):990-997.
• [30] Alapati S,Rao PS. Historical aspects of transcatheter occlusion of atrial septal defects[M]//Rao PS. Atrial Septal Defect. Rijeka:IntechOpen, 2012:57-84.
• [31] Toumanides S,Sideris EB,Agricola T,et al. Transcatheter patch occlusion of the left atrial appendage using surgical adhesives in high-risk patients with atrial fi brillation[J]. J Am Coll Cardiol,2011,58(21):2236-2240.
• [32] Duong-Hong D,Tang YD,Wu W,et al. Fully biodegradable septal defect occluder-a double umbrella design[J]. Catheter Cardiovasc Interv,2010,76(5):711-718.
• [33] Wu W,Yip J,Tang YD,et al. A novel biodegradable septal defect occluder:the"Chinese Lantern"design,proof of concept[J]. Innovations(Phila),2011,6(4):221-230.
• [34] Du Y,Xie H,Shao H,et al. A prospective,single-center,phase I clinical trial to evaluate the value of transesophageal echocardiography in the closure of patent foramen ovale with a novel biodegradable occluder[J]. Front Cardiovasc Med,2022,9:849459.
• [35] Song L,Shi P,Zheng X,et al. Echocardiographic characteristics of transcatheter closure of patent foramen ovale with mallow biodegradable occluder:a single-center,phase III clinical study[J]. Front Cardiovasc Med,2022,9:945275.
• [36] Hara H,Jones TK,Ladich ER,et al. Patent foramen ovale closure by radiofrequency thermal coaptation:first experience in the porcine model and healing mechanisms over time[J].Circulation,2007,116(6):648-653.
• [37] Sievert H,Ruygrok P,Salkeld M,et al. Transcatheter closure of patent foramen ovale with radiofrequency:acute and intermediate term results in 144 patients[J]. Catheter Cardiovasc Interv,2009,73(3):368-373.
• [38] Krishnan SC,Salazar M. Septal pouch in the left atrium:a new anatomical entity with potential for embolic complications[J].JACC Cardiovasc Interv,2010,3(1):98-104.
• [39] Di Biase L,Burkhardt JD,Horton R,et al. Closure of foramen ovale triggered by injury to tunnel surfaces of septum primum and secundum[J]. J Interv Card Electrophysiol,2019,55(1):63-71.
• [40] Sievert H,Fischer E,Heinisch C,et al. Transcatheter closure of patent foramen ovale without an implant[J]. Circulation,2007,116(15):1701-1706.
• [41] Ruiz CE,Kipshidze N,Chiam PTL,et al. Feasibility of patent foramen ovale closure with no-device left behind:first-in-man percutaneous suture closure[J]. Catheter Cardiovasc Interv,2008,71(7):921-926.
• [42] Majunke N,Baranowski A,Zimmermann W,et al. A suture not always the ideal solution:problems encountered in developing a suture-based PFO closure technique[J]. Catheter Cardiovasc Interv,2009,73(3):376-382.
• [43] Gaspardone A,De Marco F,Sgueglia GA,et al. Novel percutaneous suture-mediated patent foramen ovale closure technique:early results of the NobleStitch EL Italian Registry[J]. EuroIntervention,2018,14(3):e272-e279.
• [44] Gaspardone A,Sgueglia GA,De Santis A,et al. Predictors of residual right-to-left shunt after percutaneous suture-mediated patent fossa ovalis closure[J]. JACC Cardiovasc Interv,2020,13(18):2112-2120.
• [45] Beneduce A,Ancona MB,Moroni F,et al. Suture-mediated percutaneous patent foramen ovale closure:a systematic transesophageal echocardiography study[J]. EuroIntervention,2022,18(1):63-67.
• [46] Chaudhry-Waterman N,Shapiro S,Thompson J. Use of the NobleStitch?EL for the treatment of patients with residual right-to-left shunt following device closure of PFO[J]. Clin Case Rep,2021,9(4):1929-1932.